Tree farmers and the marketing group that supports them want more Americans to buy live-cut trees. A new Home Depot ad gave them holiday hope. By Kevin Draper Milk had “Got Milk?” Beef had “Beef: It’s ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Each year, a tree is selected and driven across state lines to Manhattan's Rockefeller Center. The iconic tree has come from Canada, New York, and various states across the Northeast. Few holiday ...

Christmas is nearly here and you’re thinking about presents, house decorations and putting up a tree. What’s your tree plan this year? Lugging home a Christmas tree and decorating it in the living ...

Paying for gifts, decorations and gingerbread houses can become quite expensive, so the U.S. Department of the Interior is hoping to ease some financial burden by making Christmas trees more ...

One of the most difficult decisions you'll probably make this holiday season is between real and fake. Should you get a real Christmas tree, as more than 30 million people will do this year, according ...

The Ohio State Buckeyes' mascot is named after the Ohio buckeye, the state tree. Ohio buckeye trees can grow up to 60 feet tall and drop their nuts in the fall. All parts of the buckeye tree are ...

Shopping for a Christmas tree? Eleven national forests across California are issuing permits to people hoping to decorate their homes with evergreens this holiday season. The U.S. Forest Service ...

This is read by an automated voice. Please report any issues or inconsistencies here. A fire that ignited during the government shutdown burned hundreds of Joshua trees. The iconic, twisty trees are ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...